Camazepam versus placebo. A double-blind clinical study on geriatric patients suffering from psychic complaints.
Abstract:
Camazepam, a dimethylcarbamic derivative of benzodiazepines, was studied on forty geriatric in-patients suffering from psychic disorders concerning anxiety and depression. Patients were treated with placebo and 30 mg of camazepam per day for 20 days using the double-blind method. The patients were assessed using a simplified rating scale with target symptoms of anxiety and depression. Statistical evaluation was performed with general Student's t-test for paired samples and chi2 test. Both groups of patients improved with camazepam and placebo. Camazepam 30 mg per day was more effective than placebo to a statistically significant degree.
Related Concept Videos
The Placebo Effect
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age

